Contact Information:

Media Contact

Winfried Meissner
winfried.meissner@med.uni-jena.de
49-170-336-5495

http://www.euroanaesthesia.org




Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.

PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION
RSS - Press News Release
Add Press Release

American surgery patients -- more pain medication, yet more pain!


2015-06-01
(Press-News.org) New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. The study is by Drs Winfried Meissner and Ruth Zaslansky, University Hospital Jena, Germany, and Dr C. Richard Chapman Utah, Pain Research Center, Salt Lake City, USA. All researchers are part of the international PAIN OUT** research group.

Poorly controlled pain after surgery is a major problem internationally despite efforts to improve it. American hospitals regularly assess pain because it is a requirement for accreditation. Regular pain assessment is regarded as a cornerstone for good pain management as it allows gauging of a patient's needs for treatment. Prior to this study, the research team believed that because pain assessment is an accreditation requirement in the USA, there would be meaningfully lower pain reports on the first day after surgery in USA patients compared with other countries, where pain measurement is not uniformly an accreditation requirement.

Using the PAIN-OUT international acute pain registry** to examine perioperative pain control in a large group of patients undergoing different orthopaedic surgical procedures, the authors compared patient reported outcomes in a pooled patient sample from four American (n= 1011) (different regions of the US) versus 45 International hospitals (INT) hospitals (n = 28,510). The international hospitals involved in the study were based in Belgium, France, Germany, Italy, Spain, Sweden, Switzerland, Moldovia, Romania, Malaysia, Ukraine, Serbia, Israel and the UK.

The study found that American patients, contrary to prediction, had higher mean worst pain scores than INT patients (7.5 on a standard 11 point pain measurement scale versus 5.2). American patients also reported that they felt 'greater participation in decisions about pain treatment' and that the pain had a more severe effect on their level of anxiety and helplessness. Yet, there were no differences in other outcomes, such as the time patients reported spending in severe pain on the first day after surgery or in the extent of relief provided by pain treatments. Outcomes were measured using standard rating scales employed in clinical pain studies.

These findings were surprising and so the authors did further analyses to check pain management practices provided to American patients as compared with INT patients. They found that American patients were actually receiving more opioid medication in the different phases of surgery - before hospitalisation, just before surgery and during the first day after surgery. They also received more regional analgesia after surgery. INT patients received more non-opioid medications in some phases of treatment.

Since high amounts of opioids can sensitise patients to nociception (meaning they experience worse pain), the authors then checked to see if American patients receiving the lowest opioid doses also experienced more pain. They found that the 25% of USA patients receiving the lowest doses of opioids had a higher worse pain score (6.62) than the 25% of INT patients receiving the lowest doses of opioids (4.93). This indicates that sensitisation by opioids is not necessarily the reason for the observed differences.

The authors say: "The higher mean worst pain score in USA patients on the first day after orthopaedic surgery does not have a simple explanation. USA patients receive more pain medication than international patients and yet report worse pain. This merits further investigation."

The authors say that, although the hospitals were not selected by strict random sampling, they are reasonably representative of practices in the countries they represent. Another limitation they highlight is that pain was assessed once on the first post-operative day and so it was not possible know how the pattern of pain responses on subsequent days after surgery emerged.

The authors conclude: "The findings of this study are puzzling as American patients were treated according to current clinical practice guidelines to a greater extent compared to INT patients. Their pain is regularly assessed; they received more opioids and regional analgesia. Are the differences cultural? Perhaps pain is measured mechanistically and this in itself is insufficient in procuring good management of pain? Could frequent pain measurement draw patient's attention to the pain and intensify the experience? Maybe opioids sensitise some aspects of the post-surgical experience of pain? Further research is needed to understand the findings."

They add: "Registries such as PAIN OUT allow healthcare providers to assess the effect of care in the clinical routine on outcomes and to find out how their patients' outcomes compare to national and international benchmarks. Participation in PAIN OUT is open to healthcare providers, worldwide."

INFORMATION:


ELSE PRESS RELEASES FROM THIS DATE:

Preoperative statins reduce mortality in coronary artery bypass graft surgery

2015-06-01
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. The study is reported by Assistant Professor Dr. Robert Sanders, Anesthesiology & Critical care Trials & Interdisciplinary Outcomes Network (ACTION), Department of Anesthesiology, University of Wisconsin, Madison, WN, USA, and Drs. Puja Myles ...

Immunotherapy drug improves survival for common form of lung cancer

2015-06-01
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies. Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab ...

Contact lens wearers note: Your eyes may get more infections because their microbiomes changed

2015-05-31
Using high-precision genetic tests to differentiate the thousands of bacteria that make up the human microbiome, researchers at NYU Langone Medical Center suggest that they have found a possible -- and potentially surprising -- root cause of the increased frequency of certain eye infections among contact lens wearers. In a study report on their work to be presented at the annual meeting of the American Society for Microbiology on May 31 in New Orleans, NYU Langone researchers say they have identified a diverse set of microorganisms in the eyes of daily contact lens wearers ...

Immunotherapy combo increases progression-free survival in advanced melanoma patients

2015-05-31
CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each ...

Removing more breast tissue reduces by half the need for second cancer surgery

2015-05-30
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago. Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...

Targeted drug can 'diminish the suffering' of myelofibrosis say Mayo Clinic researchers

2015-05-30
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...

Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

2015-05-30
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone. The announcement was made at ...

EARTH: Rock stars -- Geologists on the silver screen

2015-05-29
Alexandria, VA - As this summer's blockbuster movie season gets underway, EARTH Magazine asks an important question: In movies, "are geologists portrayed as heroes or villains?" The topic of how geologists are portrayed in film has been oft-debated around a campfire, or over a frosty beverage at the end of a day of fieldwork, but now four scientists bring some serious analysis to the subject in the June issue feature, "Rock Stars - Geologists on the Silver Screen." The authors - all geologists in the Department of Earth Sciences at the University of Gothenburg in Sweden ...

Rapid and cost-effective chromosomal phasing is possible with Droplet Digital PCR Technology

2015-05-29
Hercules, CA -- May 29, 2015 -- Researchers at Harvard Medical School and the Digital Biology Center at Bio-Rad Laboratories, Inc. have developed a rapid, scalable, and cost-effective method for chromosomal phasing that provides researchers with a new method to determine if genetic variants are linked on the same chromosome. Using Bio-Rad's Droplet Digital PCR (ddPCRTM) technology, the Drop-Phase method can rapidly determine the chromosomal phase of allelic markers hundreds of kilobases apart. This ability may provide new insights into the cause, penetrance, and severity ...

Genetic biomarker may predict cancer patients' response to immunotherapy drug

2015-05-29
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells. Results of the trial with pembrolizumab, marketed as Keytruda, ...

LAST 30 PRESS RELEASES:

How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[Press-News.org] American surgery patients -- more pain medication, yet more pain!
Press-News.org is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.